Skip to main content
Premium Trial:

Request an Annual Quote

NYU Langone Health Gets FDA Clearance for Solid Tumor Gene Sequencing Test

NEW YORK — NYU Langone Health said on Thursday that it has received 510(k) clearance from the US Food and Drug Administration for its Genome PACT genetic test for solid tumors.

Genome PACT — short for profiling of actionable cancer targets — uses next-generation sequencing to detect cancer-linked mutations in 607 genes in tumor cells in order to match patients with approved treatments targeting their specific disease-causing mutations.

The test was developed in collaboration with healthcare tech firm Philips, which helped build an interface between the test and NYU Langone Health's electronic medical records system. It is currently only FDA-cleared for use in patients at NYU Langone Health.

"The FDA decision on PACT reaffirms the goal behind its design, which was to provide our patients with the best understanding of the genetic changes driving their cancers," NYU Langone Health's Matija Snuderl, who designed the test, said in a statement. "Knowing the genetics of their tumor can help to determine which therapies will work for a given patient and their eligibility for specific clinical trials."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.